Biologics for evaluating drug targets: an interview with Michael Schwenkert

In this interview, Michael Schwenkert (Bio-Rad Laboratories; CA, USA) discusses the use of neo-epitope specific antibodies in the field of drug discovery and development.

Go to the profile of RxNet
Feb 08, 2018
0
0

In this interview, Michael Schwenkert (Bio-Rad) talks to Bioanalysis Zone about the poster he presented at EBF 2017 (Barcelona, Spain).  Learn more about the use of antibodies to evaluate drug targets and the development of neo-epitope specific antibodies at Bio-Rad.

Did you enjoy this interview? You may also like:
Go to the profile of RxNet

RxNet

A network for the drug discovery and development community, Future Science Group

Your source for the latest news and views from the fields of drug discovery and medicinal chemistry.

No comments yet.